

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司\*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

### POSITIVE PROFIT ALERT

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders and potential investors of the Company that based on the preliminary review on the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2013, which are in the course of being finalised and are yet to be confirmed, the unaudited consolidated profit attributable to owners of the parent for the six months ended 30 September 2013 is expected to record a significant increase as compared with that for the six months ended 30 September 2012.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司\*) (the “**Company**”) and together with its subsidiaries, the “**Group**”) wishes to inform the shareholders and potential investors of the Company that based on the preliminary review on the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2013, the unaudited consolidated profit attributable to owners of the parent for the six months ended 30 September 2013 is expected to record a significant increase as compared with that for the six months ended 30 September 2012. This expected significant profit increase is primarily attributable to, among other things, the increase in gross profit resulting from the increase in the Group’s turnover, the gain from change in fair value of investments held-for-trading and the decrease in fair value gains on investment properties for the six months ended 30 September 2013 as compared with the corresponding period in 2012.

\* For identification purpose only

The information contained in this announcement is only based on the preliminary review on the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2013. The Company is still in the course of preparing and finalising such accounts, which are yet to be confirmed. The unaudited consolidated interim results of the Group for the six months ended 30 September 2013 are expected to be announced by the Company before the end of November 2013.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**WAI YUEN TONG MEDICINE HOLDINGS LIMITED**  
(位元堂藥業控股有限公司)  
**Chan Chun Hong, Thomas**  
*Managing Director*

Hong Kong, 7 November 2013

*As at the date of this announcement, the executive directors of the Company are Mr. Tang Ching Ho, Mr. Chan Chun Hong, Thomas and Ms. Tang Mui Fun and the independent non-executive directors of the Company are Mr. Leung Wai Ho, Mr. Siu Man Ho, Simon, Mr. Yuen Chi Choi and Mr. Cho Wing Mou.*

\* For identification purpose only